BioLineRx Ltd. (BLRX)
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
BioLineRx Ltd.
- 2.8%
- 136.5K
- 17.18
Float 4.80M · Signal8 dilution snapshot · Sep 25, 2026
The cost to borrow BLRX shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 35.5%
- 242
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 136.5K sh |
| Oct 15, 2026 | 136.9K sh |
| Sep 30, 2026 | 145.6K sh |
| Sep 15, 2026 | 145.8K sh |
| Aug 31, 2026 | 135.9K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 27, 2026 | 242 sh |
| Oct 21, 2026 | 399 sh |
| Oct 19, 2026 | 916 sh |
| Oct 7, 2026 | 1.9K sh |
| Oct 6, 2026 | 140 sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 17, 2026 | 35.5% |
| Nov 16, 2026 | 7.8% |
| Nov 13, 2026 | 48.2% |
| Nov 12, 2026 | 52.0% |
| Nov 11, 2026 | 66.6% |
130 calendar days requested; 92 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for BLRX: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 136,538 BLRX shares were sold short (2.84% of a 4.80M-share float, 17.18 days to cover).